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AbbreviATions
5-FU 5-fluorouracil 
bCD bacterial cytosine deaminase 
GCV ganciclovir 
YCD yeast cytosine deaminase 
HSV-1 TK: herpes simplex type 1 
 thymidine kinase 
CPNP calcium phosphate nanoparticles 
CEA carcinoembryonic antigen 
Commentary to:
Tissue Specific Expression of Suicide Genes Delivered 
by Nanoparticles Inhibits Gastric Carcinoma Growth
T. Liu, G. Zhang, Y.-H. Chen, Y. Chen, X. Liu, 
J. Peng, M.H. Xu and J.W. Yuan
The global statistics regarding incidences of and deaths from gastric cancer are stag-
gering: it has accounted for as many as 650,000 deaths per year,1 and among cancer-related 
deaths, it ranks as the second leading cause, behind only lung cancer.2,3 Five-year survival 
rates hover around a meager 20% since traditional chemotherapies such as 5-fluorouracil 
(5-FU) and doxorubicin do not exhibit sufficient therapeutic properties in advanced-
stages, often when a majority of cases are diagnosed.1 Based on these dire statistics, it is 
obvious that new therapies must be developed to combat this disease, and one emerging 
approach is targeted suicide gene therapy.
Suicide gene therapy, where nonmammalian genes convert normally nontoxic prodrugs 
into toxic forms, is a promising form of therapy that is now in Phase I clinical trials for 
the treatment of prostate and colorectal cancer.4,5 Bacterial cytosine deaminase (bCD) 
and herpes simplex type 1 thymidine kinase (HSV-1 TK) are two suicide genes known 
for their ability to convert nontoxic 5-fluorocytosine into toxic 5-FU and nontoxic ganci-
clovir (GCV) into toxic phosphorylated GCV, respectively. The resulting metabolites are 
integrated into the DNA and RNA of cells, leading to strand termination and eventual 
cell death.6 While bCD is capable of acting as a suicide gene, it has been reported that 
yeast CD (yCD) is much more powerful in this regard.7,8 Recently, a novel fusion suicide 
gene was developed consisting of both yCD and HSV-1 TK, termed yCDglyTK; when 
expressed in tumor cells, it performed prodrug conversion while rendering the cells more 
sensitive to radiation therapy.6
Gene therapy is, of course, most effective when delivery is both efficient and safe, 
especially when dealing with cancer. However, it has often proven difficult to find a balance 
between efficiency and safety. For example, viral vectors, which encompass some of the 
most common methods used in gene therapy due to their superior transfection efficiency, 
often induce an immune response9 and can even cause patient death.10 As a result, much 
recent work has been devoted to non-viral delivery methods, including cationic liposomes 
and calcium phosphate nanoparticles (CPNP). While cationic liposomes show potential 
regarding transfection efficiency and the size of DNA they can deliver, they can be toxic 
under certain conditions.11 Conversely, Liu et al have recently shown that positively 
charged CPNP can also bind negatively charged DNA effectively, and these complexes are 
able to enter the cell to deliver the DNA with minimal toxicity.12
While efficient delivery of suicide genes is an attractive approach to treating gastric 
cancer, lack of tumor specificity can still lead to undesirable side effects. Preferably, the 
suicide genes would affect only malignant cells, while sparing normal, healthy cells. As 
many cancers, namely gastric, colon, breast and ovarian, overexpress the carcinoembryonic 
antigen (CEA) protein [reviewed in Ref. 13] it has come to light that selective therapy 
for colorectal cancer can be achieved using a CEA promoter that drives the expression of 
either bCD14 or yCD.15 In the December 2006 issue of Cancer Biology and Therapy, Liu 
et al describe a method of efficiently and selectively delivering the yCDglyTK suicide gene 
by placing it under the control of a CMV-enhanced CEA promoter (CV) and complexing 
it with CPNP. The group envisioned that once the genes were efficiently transferred via 
the CPNP, only cells expressing CEA, e.g., gastric cancer cells, would undergo cytotoxic 
effects after 5-FC was administered and subsequently converted to 5-FU.
The authors report that in CV-yCDglyTK-positive SGC7901 gastric cancer cells (CEA 
positive) cell viability was only 10.2%, while in CV-yCDglyTK-positive Hela cells (CEA 
negative) viability was 98% following the administration of 5-FC. When CPNP were used 
to deliver the suicide gene, SGC7901 cells exhibited only 25.36% viability, demonstrating 
the efficiency of CPNP delivery. Intriguingly, when stably transfected CV-yCDglyTK 
SGC7901 cells were mixed with untransfected SGC7901 cells, a significant “bystander 
effect” occurred after five days of treatment with 5-FC. Cell death was as high as 38.5% 
even when only 5% of the cells in the mixture were CV-yCDglyTK positive. In vivo 
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studies further confirmed the therapeutic potential of combining 
suicide genes with non-viral CPNP delivery vehicles. SGC7901 
xenografts that received CPNP-CV-yCDglyTK injections showed 
marked tumor regression as compared to the untransfected control 
group, when both groups were treated with 5-FC.
Collectively, these results indicate that this novel, targeted system 
shows promise regarding the development of therapies for gastric 
cancers, or other malignancies that overexpress the CEA antigen. 
Since bCDglyTK and yCDglyTK fusion gene therapies have both 
been found to leave malignancies more susceptible to radiation 
therapy,10,16,17 a natural next step for this group could be to utilize 
5-FC, GCV and radiopharmaceuticals to investigate the possibility 
of synergistic and/or radiosensitization effects within their novel 
targeted system.
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